Compare MVIS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MVIS | CRBU |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.2M | 179.7M |
| IPO Year | 2010 | 2021 |
| Metric | MVIS | CRBU |
|---|---|---|
| Price | $0.65 | $2.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.25 | ★ $10.75 |
| AVG Volume (30 Days) | ★ 3.4M | 1.3M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.91 | 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $664,000.00 | N/A |
| Revenue This Year | $529.06 | $1.63 |
| Revenue Next Year | $168.46 | $10.93 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $0.73 |
| 52 Week High | $1.73 | $3.53 |
| Indicator | MVIS | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 53.56 |
| Support Level | $0.51 | $1.70 |
| Resistance Level | $0.73 | $2.26 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 51.89 | 50.91 |
Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars. Geographically, the company operates in United States, Germany, and Other foreign countries.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.